Results 211 to 220 of about 18,401,385 (385)
The emerging role of clinimetrics in pediatric rheumatology. [PDF]
Pediatr Rheumatol Online JAnton J, Ravelli A.
europepmc +1 more source
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Pain, 2003 R. Dworkin +34 more
semanticscholar +1 more source
Digital and self‐reported reading measures in Brazilians with Alzheimer's disease: An exploratory correlational study [PDF]
Guilherme Briczinski Souza +6 more
openalex +1 more source
On unbounded invariant measures of stochastic dynamical systems [PDF]
, 2015 Sara Brofferio, Dariusz Buraczewski
openalex +1 more source
Molecular Oncology, EarlyView.Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser +14 more
wiley +1 more source
Impact of Infection Prevention Measures on Patients With Dementia in Care Facilities During the COVID-19 Pandemic. [PDF]
Geriatr Gerontol IntIwamoto Y +4 more
europepmc +1 more source
Calculation of signal detection theory measures
Behavoir research methods, instruments & computers, 1999 H. Stanislaw, N. Todorov
semanticscholar +1 more source
Measuring Decentering and Attachment in a University Clinical Sample
, 2007 Luis Enrique Cortés Pérez
openalex +1 more source
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Molecular Oncology, EarlyView.The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu +18 more
wiley +1 more source